Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 2.917
Filtrar
1.
Sheng Wu Gong Cheng Xue Bao ; 36(5): 879-890, 2020 May 25.
Artigo em Chinês | MEDLINE | ID: mdl-32567271

RESUMO

Human parvovirus B19 (B19 virus) is one of the two parvoviruses that cause human diseases. As an important pathogen to humans, it causes infectious erythema in children, acute aplastic anemia, fetal edema and death. In this review, we focus on the recent advances in the molecular virology of B19V, such as viral genotypes, viral receptor, genomic features and viral replication, viral transcription and post-transcription regulation, viral nonstructural and structural protein features and functions, viral diagnosis and antiviral agents, to provide reference for further study of B19 pathogenesis mechanisms, treatment and diagnostic strategies.


Assuntos
Parvovirus B19 Humano , Virologia , Antivirais , DNA Viral/genética , Eritema Infeccioso/diagnóstico , Eritema Infeccioso/virologia , Genótipo , Humanos , Parvovirus B19 Humano/genética , Virologia/tendências , Replicação Viral
2.
Medicine (Baltimore) ; 99(17): e19832, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-32332630

RESUMO

BACKGROUND: Human parvovirus B19 (B19V) infection exhibits a broad range of clinical outcomes. Blood transfusion is a common route of B19V transmission. However, information about the overall prevalence of B19V infection and B19V genotypes among blood donors in mainland China is lacking. METHODS: This meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search for studies reporting the B19V prevalence among blood donors in mainland China from 2000 to 2018 was performed. The prevalence of B19V was estimated through a meta-analysis of the relevant literature. A comprehensive meta-analysis program was used for data processing and statistical analysis. RESULTS: Twenty-one eligible articles were included, involving 48,923 participants assessed for B19V-DNA, 12,948 participants assessed for anti-B19V immunoglobulin M (IgM), and 8244 participants assessed for anti-B19V immunoglobulin G (IgG). The analysis revealed the pooled estimates of the prevalence rates of B19V-DNA, anti-B19V IgM, and anti-B19V IgG among blood donors to be 0.7% (95% confidence interval [CI] 0.2-2.4%), 2.7% (95% CI 1.7-4.3%), and 33.6% (95% CI 28.2-39.4%), respectively. Moreover, phylogenetic analyses indicated that 142 of 169 (84.0%) B19V isolates belonged to Genotype 1. CONCLUSIONS: The overall prevalence of B19V among blood donors is not high in mainland China, and most isolates belong to Genotype 1.


Assuntos
Doadores de Sangue , Genótipo , Infecções por Parvoviridae/epidemiologia , Infecções por Parvoviridae/virologia , Parvovirus B19 Humano/genética , Transfusão de Sangue , China/epidemiologia , DNA Viral/sangue , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Prevalência
3.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi ; 36(1): 75-80, 2020 Jan.
Artigo em Chinês | MEDLINE | ID: mdl-32314727

RESUMO

Human parvovirus B19 (PVB19) is a small single strand DNA virus distributed throughout the world, with its encoded products being three known proteins. There is conclusive evidence that PVB19 infection is a crucial inducement of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Hashimoto's thyroiditis (HT), myasthenia gravis (MG) and other autoimmune diseases (AIDs). Recent studies have confirmed that anti-B19-VP1u-IgG antibody is able to increase the activity of cytokines such as interleukin 1 (IL-1), tumor necrosis factor α (TNF-α), matrix metalloproteinase-9 (MMP9); PVB19 protein NS 1 and VP1u are capable of inducing the expression of IL-6; PVB19 can induce the production of Th17 cell-related cytokines, resulting in the decrease of IFN-gamma levels and the increase of IL-4 levels in plasma. In this paper, the structure of PVB19, the mechanism of human infection and the relationship between PVB19 and AIDs are summarized.


Assuntos
Doenças Autoimunes/virologia , Parvovirus B19 Humano/patogenicidade , Artrite Reumatoide/virologia , Citocinas/imunologia , Doença de Hashimoto/virologia , Humanos , Lúpus Eritematoso Sistêmico/virologia , Miastenia Gravis/virologia
4.
Rinsho Ketsueki ; 61(3): 215-222, 2020.
Artigo em Japonês | MEDLINE | ID: mdl-32224580

RESUMO

Refractory viremia/viral disease is a major life-threatening complication that may arise among patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This study aimed to clarify the therapeutic effect of high-dose polyclonal intravenous immunoglobulin (IVIG) against viremia/viral diseases after allo-HCT. We conducted a pilot study to investigate the therapeutic effect of 400 mg/kg of IVIG given for 5 consecutive days against refractory viremia/viral disease after allo-HCT. Overall, 7 patients were drug-resistant and the other 7 had not previously received any drug for their viremia/viral disease. All patients completed the 5-day therapy regimen of IVIG. A complete response at Day 56 was observed for 8 of 14 patients (57.1%). Additionally, 10 of 14 patients (71.4%) were alive at Day 56, although only one death occurred due to the viremia/viral disease. Remarkably, all 3 cases who developed exogenous viremia/viral diseases including respiratory syncytial virus pneumonia/bronchitis and human parvovirus B19 viremia achieved a complete response, suggesting that high-dose polyclonal IVIG may be more effective against exogenous viruses rather than endogenous ones. Congestive heart failure was observed in 1 patient. High-dose polyclonal IVIG could be an effective and feasible therapy for refractory viremia/viral disease after allo-HCT.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Viremia/tratamento farmacológico , Humanos , Imunoglobulinas Intravenosas , Parvovirus B19 Humano , Projetos Piloto , Viremia/etiologia
5.
Praxis (Bern 1994) ; 109(1): 42-46, 2020 Jan.
Artigo em Alemão | MEDLINE | ID: mdl-31910759

RESUMO

CME Rheumatology 20: Parvovirus B19-Induced Tenosynovitis? Abstract. In this case presentation we discuss diagnostic algorithms and differential diagnoses in undifferentiated tenosynovitis. We present a case of a patient with chronic tenosynovitis in the 4th extensor tendon compartment. With unremarkable anamnesis and due to normal laboratory results a «seronegative (RF), ACPA (CCP)-negative tenosynovitis without arthritis¼ had been reported. Diagnostic and therapeutic tenosynovectomy was performed. Histologic processing revealed a positive PCR for parvovirus B19. We discuss articular and extraarticular manifestations. A parvovirus B19-associated manifestation in the musculoskeletal system is usually self-limiting. The therapy should be carried out symptomatically. In our patient there was a marked local finding, so that the complete tenosynovectomy followed by a single steroid injection led to a persistent restitutio ad integrum.


Assuntos
Artrite , Infecções por Parvoviridae , Parvovirus B19 Humano , Tenossinovite , Diagnóstico Diferencial , Humanos , Infecções por Parvoviridae/complicações , Reação em Cadeia da Polimerase , Tenossinovite/virologia
7.
Biochem Genet ; 58(1): 63-73, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31250332

RESUMO

Chronic inflammation plays a prominent role in cancer initiation and development. On the other hand, the Inflammation can be established by a number of factors such as viral infections. Parvovirus B19 (B19V) is a pathogen with widespread infection, which infects bone marrow erythroid progenitor cells. It has been shown that B19V can also enter human bone marrow mesenchymal stem cells (BM-MSCs). In this study, we hypothesized that BM-MSCs as the main cellular component of bone marrow niche may be induced to secret pro-inflammatory cytokines after B19V infection. BM-MSCs were cultured up to passage 3. The cells were then subjected to nucleofection to transfer a plasmid containing B19V genome. After 36 h, total RNA was extracted and the expression levels of IL-1ß, IL-6, TNF-α and NF-κB genes were examined using qRT-PCR. Data analysis showed the significant increase in expression levels of all studied genes in the B19V-transfected cells (P < 0.05). Although further researches are required, our findings for the first time suggest the importance of B19V infection to establish an inflammatory microenvironment in the bone marrow and its involvement in inflammation-related diseases. Finally, based on our results, molecular assay to diagnose B19V infection of BM-MSCs prior to stem cell therapy is strongly recommended.


Assuntos
Citocinas/genética , Expressão Gênica , Células-Tronco Mesenquimais/virologia , Infecções por Parvoviridae/genética , Infecções por Parvoviridae/patologia , Parvovirus B19 Humano , Linhagem Celular , Humanos , Inflamação/genética , Inflamação/virologia , Infecções por Parvoviridae/diagnóstico , Regulação para Cima
8.
Medicina (Kaunas) ; 55(12)2019 Dec 04.
Artigo em Inglês | MEDLINE | ID: mdl-31817247

RESUMO

Background and Objectives: Viral infections are frequently cited as a major environmental factor implicated in thyroid gland diseases. This work aimed to estimate the presence of B19V infection in patients with thyroid gland disorders. Materials and Methods: Thyroid gland tissue and blood samples of 50 patients with autoimmune thyroid gland diseases (AITDs), 76 patients with non-autoimmune thyroid gland diseases (non-AITDs), and 35 deceased subjects whose histories did not show any autoimmune or thyroid diseases (control group) were enrolled in the study. Virus-specific IgM and IgG were detected using ELISA, and the presence and viral load of B19V in the tissue and blood were detected using PCRs. Results: B19V IgG antibodies were detected in 35/50 AITDs patients and in 51/76 non-AITDs patients, and B19V IgM antibodies were detected in 1/50 patients with AITDs and in none of the 76 patients with non-AITDs. The B19V NS sequence was found in the tissue DNA of 10/50 patients with AITDs, in 30/76 with non-AITDs, and in 1/35 control group individuals. The median B19V load in the tissue of patients with AITDs and non-AITDs was 423.00 copies/µg DNA (IQR: 22.50-756.8) and 43.00 copies/µg DNA (IQR: 11.50-826.5), respectively. The viral load in one of the 35 nPCR B19V-positive thyroid tissue samples from the deceased subjects was 13.82 copies/µg DNA. The viral load in the tissue of patients with AITDs was higher than in whole blood, which possibly indicates B19V persistency in thyrocytes (p = 0.0076). Conclusion: The fact that the genoprevalence of B19V NS was significantly higher in patients with non-AITDs compared to the control group and in the thyroid gland tissue of patients with AITDs, and that the non-AITDs viral load was higher than in tissue derived from the control group individuals, suggest the possibility that B19V infection could be involved in the development of thyroid gland diseases.


Assuntos
Parvovirus B19 Humano/genética , Doenças da Glândula Tireoide/virologia , Glândula Tireoide/virologia , Carga Viral/genética , Adulto , Idoso , DNA Viral/sangue , Ensaio de Imunoadsorção Enzimática/métodos , Feminino , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Masculino , Pessoa de Meia-Idade , Parvovirus B19 Humano/imunologia , Reação em Cadeia da Polimerase/métodos , Prevalência , Doenças da Glândula Tireoide/sangue , Doenças da Glândula Tireoide/epidemiologia , Doenças da Glândula Tireoide/patologia , Glândula Tireoide/imunologia , Glândula Tireoide/patologia , Viroses/sangue , Viroses/epidemiologia , Viroses/patologia
9.
Clin Lab ; 65(12)2019 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-31850715

RESUMO

BACKGROUND: Parvoviruses are small DNA viruses causing erythema infectiosum, which is known as the fifth disease. The aim of this study was to investigate the presence of Parvovirus B19 DNA by Real-Time-PCR retrospectively in clinical samples of children diagnosed as acute leukemia and aplastic anemia when investigating the cause of pancytopenia and to investigate its relationship with the clinical manifestations. METHODS: The study samples were collected between March 2014 and March 2018 in Gazi University, Faculty of Medicine, Department of Pediatric Hematology. Sixty pediatric patients; 37 males and 23 females, were included in the study. Nucleic acid isolation was performed by using MagNA-Pure Compact Nucleic Acid Isolation Kit (Roche, Germany). Extracted DNA was studied with LightCycler® 2.0 using the Real-Time PCR method and LightCycler® Parvovirus B19 Quantification Kit (Roche, Germany), and the results were evaluated quantitatively. Parvovirus B19 DNA detection interval of the kit was 101 - 106 copies/mL. RESULTS: Sixty serum samples were investigated and 8.3% (5/60) Parvovirus B19 DNA positivity was determined. Of the five patients with Parvovirus B19 DNA positivity, three had acute lymphoblastic leukemia and two were diagnosed as aplastic anemia. Regarding viral load; 2/5, 1/5, 1/5, and 1/5 of the samples had a viral load of 102, 103, 104, and 105 copies/mL, respectively. Parvovirus B19 DNA positivity was detected in samples from March (2/5), April (2/5), and August (1/5). CONCLUSIONS: Patients with acute leukemia and aplastic anemia in childhood using immunosuppressive drugs, blood, and blood products during chemotherapy, encounter Parvovirus B19 infections in the follow-up period and are diagnosed by serological and molecular methods. As a result of the study, we suggest that the detection of Parvovirus B19 DNA by Real-Time PCR method in children being admitted with pancytopenia and diagnosed as acute leukemia and aplastic anemia is useful in the follow-up and treatment.


Assuntos
Anemia Aplástica/diagnóstico , Eritema Infeccioso/diagnóstico , Pancitopenia/diagnóstico , Parvovirus B19 Humano/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , Adolescente , Anemia Aplástica/complicações , Anemia Aplástica/tratamento farmacológico , Criança , Pré-Escolar , DNA Viral/genética , DNA Viral/isolamento & purificação , Eritema Infeccioso/complicações , Eritema Infeccioso/virologia , Feminino , Humanos , Imunossupressores/uso terapêutico , Lactente , Masculino , Pancitopenia/sangue , Pancitopenia/complicações , Parvovirus B19 Humano/fisiologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Reação em Cadeia da Polimerase em Tempo Real , Estudos Retrospectivos
10.
Biomed Res Int ; 2019: 2757450, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31886191

RESUMO

Background: Parvovirus B19 (B19 V) infection had been reported to be more frequent with serious clinical outcomes in patients with sickle cell disease (SCD) than in the general population. There is a wide variation in data among the existing literature regarding the seroprevalence of B19 V in patients with SCD. These data require further summary and analyses for better accuracy. This systematic review and meta-analysis was done to estimate the seroprevalence of B19 V in patients with SCD. Methods: This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The databases of MEDLINE/PubMed, Virtual Health Library (VHL), ScienceDirect, Google Scholar, and OpenGrey were used for the systematic search. The random-effects model was used to estimate the pooled prevalence with the corresponding 95% confidence interval (CI) using OpenMeta Analyst software. Publication bias was estimated based on Begg's test, Egger's test, and examination of the funnel plot. Subgroup analyses and metaregression were used to explore the moderators of heterogeneity between studies. Results: A total of 18 studies including 2890 patients were analyzed. The overall IgG seroprevalence of B19 V infection among patients with SCD was found to be 48.8% (95% CI 39.5%-58.0%). Evidence of publication bias was not detected. Evidence of acute viral infection detected by positive IgM antibodies among the screened SCD patients was found in 8.30% (95% CI 5.20%-11.4%) of them. There was a statistically significant association between seroprevalence of B19 V and geographical areas. Conclusion: There was a high prevalence of B19 V in patients with SCD. Healthcare providers need to be aware of the magnitude of B19 V infection in patients with SCD to ensure effective management. This review could provide a comprehensive view of B19 V prevalence in this susceptible population.


Assuntos
Anemia Falciforme/sangue , Anticorpos Antivirais/sangue , Eritema Infeccioso/sangue , Estudos Soroepidemiológicos , Anemia Falciforme/imunologia , Anemia Falciforme/patologia , Anemia Falciforme/virologia , Anticorpos Antivirais/imunologia , Eritema Infeccioso/imunologia , Eritema Infeccioso/patologia , Eritema Infeccioso/virologia , Humanos , Parvovirus B19 Humano/imunologia , Parvovirus B19 Humano/patogenicidade
11.
J Investig Med High Impact Case Rep ; 7: 2324709619883698, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31635495

RESUMO

Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening condition characterized by widespread inflammation due to massive immune activation and cytokine release. It is of 2 types, primary or familial and secondary or acquired. Diagnosis is made by fulfilling 5 of 8 criteria as determined by the Histiocyte Society. Treatment includes etoposide, dexamethasone, with or without intrathecal methotrexate in the presence of neurologic involvement as well as treating the underlying cause in secondary HLH. We present a case of a 23-year-old female with congenital human immunodeficiency virus (HIV) infection who presents with nonspecific signs and symptoms of cough, fever, leukopenia, and anemia, and a high-serum parvovirus B19 DNA, later diagnosed with HLH and treated with etoposide and dexamethasone. She made clinical improvements and was successfully discharged to home after 26 days of admission.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/diagnóstico , Linfo-Histiocitose Hemofagocítica/virologia , Infecções por Parvoviridae/complicações , Parvovirus B19 Humano , Síndrome de Imunodeficiência Adquirida/congênito , Dexametasona/administração & dosagem , Dexametasona/uso terapêutico , Quimioterapia Combinada , Etoposídeo/administração & dosagem , Etoposídeo/uso terapêutico , Feminino , Humanos , Linfo-Histiocitose Hemofagocítica/diagnóstico , Linfo-Histiocitose Hemofagocítica/tratamento farmacológico , Linfo-Histiocitose Hemofagocítica/etiologia , Infecções por Parvoviridae/diagnóstico , Infecções por Parvoviridae/etiologia , Infecções por Parvoviridae/virologia , Adulto Jovem
12.
Rev Soc Bras Med Trop ; 52: e20190304, 2019 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-31508787

RESUMO

INTRODUCTION: Human parvovirus B19 (B19V) is a common pathogen, which on infection causes variety of clinical conditions from benign self-limiting exanthematous disease and other similar pathologies to fetal death. METHODS: We collected 341 serum samples between the first and fourth day after the onset of symptoms from all patients suspected of dengue fever who were attended at Regional Hospital of Tefé. Initially, patients were screened for malaria by blood smear test and negative samples were sent to Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD) situated in Manaus (AM) for dengue testing using semi-nested multiplex PCR. Further, we investigated 44 malaria and dengue-negative samples of children for B19V DNA by nested-PCR. Positive samples were analyzed by BLAST against entire public non-redundant nucleotide database and genotyped by phylogenetic analyses using neighbor-joining clustering method. RESULTS: Eight samples (18.2%) were found to be PCR positive. Fever, headache, ocular pain, and/or muscle pain were reported as the most frequent symptoms by the patients and none were diagnosed with rash at the time of sample collection. Phylogenetic analysis of major capsid protein 2 (VP2) and VP3 coding region showed high similarity with B19V genotype 1. CONCLUSIONS: Our results reveal the spread of B19V genotype 1 in Tefé. Moreover, our results emphasize the significance of laboratorial differential diagnosis using molecular techniques in patients with acute febrile, and thereby aid the health surveillance system in improving patient care even in the remote areas of Amazon.


Assuntos
DNA Viral/sangue , Dengue/diagnóstico , Infecções por Parvoviridae/diagnóstico , Infecções por Parvoviridae/virologia , Parvovirus B19 Humano/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Brasil , Criança , Pré-Escolar , Feminino , Genótipo , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Filogenia , Reação em Cadeia da Polimerase , Adulto Jovem
13.
Transpl Infect Dis ; 21(6): e13164, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31483919

RESUMO

Impaired cell-mediated, as well as antibody-mediated immunity predisposes a renal transplant recipient to a wide variety of atypical infection. With an increasing number of re-transplant, the balance between immunosuppression and the risk of recurrent disease poses a clinical and therapeutic challenge. Here, we report a successful re-transplantation in a case of parvovirus B19 infection leading to anaemia and collapsing glomerulopathy in the allograft managed with intravenous immunoglobulin (IVIG) and reduction of immunosuppression. This case emphasizes re-consideration to renal transplant after clearance of the virus in a previous renal allograft lost to PVB19 infection.


Assuntos
Eritema Infeccioso/tratamento farmacológico , Rejeição de Enxerto/terapia , Imunoglobulinas Intravenosas/uso terapêutico , Transplante de Rim/efeitos adversos , Parvovirus B19 Humano/isolamento & purificação , Aplasia Pura de Série Vermelha/etiologia , Aloenxertos/imunologia , Aloenxertos/virologia , Eritema Infeccioso/complicações , Eritema Infeccioso/imunologia , Eritema Infeccioso/virologia , Glomerulonefrite/imunologia , Glomerulonefrite/cirurgia , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/virologia , Humanos , Hospedeiro Imunocomprometido , Imunossupressores/efeitos adversos , Rim/imunologia , Rim/virologia , Doadores Vivos , Masculino , Parvovirus B19 Humano/imunologia , Recidiva , Aplasia Pura de Série Vermelha/tratamento farmacológico , Reoperação , Transplante Haploidêntico/efeitos adversos , Resultado do Tratamento , Adulto Jovem
15.
Arch Virol ; 164(11): 2775-2781, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31401693

RESUMO

Diagnosis and epidemiological analysis of human parvovirus B19 (hB19V) infections are essential for disease management in severely ill patients. This study aimed to evaluate the performance of an optimized NS1-VP1u nested PCR for detection and sequencing of viruses in clinical samples using 224 clinical and five reference samples. PCR sensitivity, specificity, and positive and negative predictive values were perfect (100%). While phylogenetic analysis of a 615 bp-long fragment demonstrated that the viruses in all of the samples belonged to genotype 1, this study confirmed that this optimized PCR could detect all known hB19V with high performance.


Assuntos
Proteínas do Capsídeo/genética , Eritema Infeccioso/diagnóstico , Eritema Infeccioso/epidemiologia , Parvovirus B19 Humano/genética , Proteínas não Estruturais Virais/genética , DNA Viral/genética , Eritema Infeccioso/virologia , Humanos , Filogenia , Reação em Cadeia da Polimerase/métodos
16.
Medicine (Baltimore) ; 98(35): e16993, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31464949

RESUMO

RATIONALE: Parvovirus B19 (PV) infection is usually symptomless and can cause benign, short-lived conditions. Anemia associated with PRCA is the most representative hematologic manifestation, but neutropenia and thrombocytopenia have been rarely reported. PATIENT CONCERNS: Three patients were admitted to the hospital with neutropenia and thrombocytopenia. The accompanying symptoms were fever, myalgia, rash, or arthralgia, and all patients were previously healthy. DIAGNOSIS: Patients were positive for PV PCR and diagnosed with PV infection. Before the diagnosis of PV infection, 2 patients underwent BM study and almost absence of erythroid progenitor cells in BM aspiration were a clue for the PV infection. Other BM findings were hypocellular marrow and a few hemophagocytic histiocytes. INTERVENTIONS: Patients received supportive care with follow-up of CBC. OUTCOMES: All 3 patients spontaneously recovered from neutropenia and thrombocytopenia within 3 weeks without severe complications. LESSONS: The evaluation of PV infection should be considered in situations where there is neutropenia and thrombocytopenia in healthy individuals even without anemia as a differential diagnosis.


Assuntos
Neutropenia/complicações , Infecções por Parvoviridae/complicações , Infecções por Parvoviridae/diagnóstico , Trombocitopenia/complicações , Adulto , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infecções por Parvoviridae/virologia , Parvovirus B19 Humano , Reação em Cadeia da Polimerase
17.
Mol Biotechnol ; 61(10): 742-753, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31317318

RESUMO

Breast cancer is a worldwide health problem, and the complexity of the disease, as well as the lack of treatment specificity, generates an urgent need for developing prophylactic and therapeutic measures. Searching for novel epitope-based approaches able to induce tumour immunity, we designed virus-like particles (VLPs) derived from Human parvovirus B19 assembled of chimeric VP2 proteins displaying two epitopes from the insulin-like growth factor-1 receptor (IGF-1R). Here, we present the generation of two chimeric VP2s that retain the stability, solubility and conditions of purification and assembly of the native VP2. We generated versatile chimeric multiepitope anti-cancer vaccine candidates, which prevented and delayed tumour growth when used in a prophylactic scheme of 4 weekly immunizations prior to 4T1 cell inoculation in female BALB/c mice. The presence of specific antibodies against the displayed epitopes suggests their participation in the protective effect; in contrast, no significant proliferative T-cell responses were recorded following stimulation by specific epitopes. The results comprise an approach whereby fusing desired epitopes from cancer to the N-terminus of B19 VP2 protein can generate a library of chimeric VP2-desired epitopes for further assembly in a designed and personalized epitope delivery system.


Assuntos
Neoplasias da Mama/prevenção & controle , Epitopos/metabolismo , Parvovirus B19 Humano/metabolismo , Receptor IGF Tipo 1/imunologia , Vacinas de Partículas Semelhantes a Vírus/administração & dosagem , Animais , Apoptose , Neoplasias da Mama/imunologia , Vacinas Anticâncer/administração & dosagem , Vacinas Anticâncer/imunologia , Proteínas do Capsídeo/genética , Proteínas do Capsídeo/metabolismo , Linhagem Celular Tumoral , Sobrevivência Celular , Epitopos/genética , Feminino , Humanos , Imunização , Camundongos , Camundongos Endogâmicos BALB C , Transplante de Neoplasias , Parvovirus B19 Humano/genética , Resultado do Tratamento , Vacinas de Partículas Semelhantes a Vírus/genética , Vacinas de Partículas Semelhantes a Vírus/imunologia
18.
Kardiologiia ; 59(7): 38-43, 2019 Jul 19.
Artigo em Russo | MEDLINE | ID: mdl-31322088

RESUMO

AIM: To assess the frequency of detection of cardiotropic virus antigens in coronary artery atherosclerotic plaques in patients with fatal myocardial infarction (MI). MATERIALS AND METHODS: We examined fragments of coronary plaques of 12 patients with fatal type 1 MI. Immunohistochemistry (IHC) of plaques was performed with the paraffin blocks using antibodies to Herpes simplex virus (HSV)-1, HSV-2, HSV-6, cytomegalovirus (CMV), parvovirus B19, adenovirus, Epstein-Barr virus and enteroviruses. RESULTS: According to the IHC all patients had virus antigens. The most common virus agents in fragments of coronary plaques were HSV-6 (10 patients) and enteroviruses (5 patients). Antigens of CMV, parvovirus B19, adenovirus, Epstein-Barr virus were not detected in any case. CONCLUSIONS: In this study viral antigens in coronary artery atherosclerotic plaques were found in all victims of fatal MI. There was no difference in the frequency of detection and type of viral agents between plaques in culprit arteries and uncomplicated atherosclerotic plaques.


Assuntos
Herpesvirus Humano 1 , Infarto do Miocárdio , Placa Aterosclerótica , Citomegalovirus , Humanos , Parvovirus B19 Humano
19.
J Microbiol Immunol Infect ; 52(4): 534-541, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31257106

RESUMO

BACKGROUND/PURPOSE: The clinical presentations of parvovirus B19 in patients with underlying diseases have greater diversity than previously healthy patients. We retrospectively identified patients with polymerase chain reaction (PCR)-confirmed parvovirus B19 infection in attempt to describe its clinical features especially in these populations. METHODS: From 2009 to 2018, patients with real-time PCR-confirmed parvovirus B19 infection were collected. Comparisons were done between previously healthy patients and patients with preexisting diseases, as well as patients with high (>5.5 × 105 copies/mL sera) and low viral loads. RESULTS: Parvovirus B19 DNA was detected in 31 patients. Fourteen (45%) patients had underlying diseases, including six (19%) with immunologic diseases, five (16%) with hematologic diseases, and three (10%) with cardiopulmonary diseases. Only seven (23%) patients received an initial impression of erythema infectiosum prior to positive PCR. A higher proportion of patients with underlying diseases presented with fatigue and pallor, and suffered from tachycardia and hepatosplenomegaly compared to previously healthy patients. Among patients with a high viral load, a substantial proportion were of older age, suffered fatigue, and anemia. There was a trend of patients with immunologic comorbidity having a higher viral load. CONCLUSION: The classical parvovirus B19 manifestations were less frequently observed in patients with a preexisting disease compared with previously healthy patients. Depending on host factors, the symptoms of parvovirus B19 infection can be multifaceted.


Assuntos
Eritema Infeccioso/complicações , Eritema Infeccioso/epidemiologia , Parvovirus B19 Humano/isolamento & purificação , Adolescente , Adulto , Anemia , Criança , Pré-Escolar , DNA Viral/sangue , Eritema Infeccioso/sangue , Eritema Infeccioso/diagnóstico , Fadiga , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Parvovirus B19 Humano/genética , Reação em Cadeia da Polimerase , Estudos Retrospectivos , Estações do Ano , Testes Sorológicos , Soro/virologia , Taquicardia , Taiwan/epidemiologia , Carga Viral , Adulto Jovem
20.
Transplant Proc ; 51(8): 2693-2696, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31351772

RESUMO

Parvovirus B19 (PVB19) has tropism to red blood cell progenitors and can be reactivated after organ transplantation. The aim of study was to describe clinical manifestations, laboratory findings, treatments used, and effectiveness in kidney recipients at Viet Duc hospital. A retrospective descriptive study was performed on 663 kidney recipients who were on regular follow-up from 2000 to 2018. PVB19 was detected by polymerase chain reaction PVB19-DNA. Effectiveness of therapy was assessed by Hemoglobin level. Nine out of 663 kidney recipients (1.4%) were diagnosed with PVB19-associated anemia. Eight of these 9 (89%) were diagnosed within the first 3 months following transplantation. All patients had normoscopic anemia; the average reticulocyte proportion and count were 0.15 ± 0.04% and 0.0039 ± 0.0011T/L, respectively. Graft dysfunction was observed in 4/9 (45%) patients. Treatment included reduction of immunosuppression, intravenous immunoglobulin (IVIG), and blood transfusion. All patients responded well to treatment except 1 (11%), who experienced relapse after using low dose of IVIG. PVB19-associated anemia usually occurred early after transplantation and was associated with very low reticulocyte proportion and count. Actual treatment was effective, but the risk of relapse was present.


Assuntos
Anemia/virologia , Transplante de Rim , Infecções por Parvoviridae , Adulto , Feminino , Humanos , Hospedeiro Imunocomprometido/imunologia , Transplante de Rim/efeitos adversos , Masculino , Pessoa de Meia-Idade , Infecções por Parvoviridae/complicações , Infecções por Parvoviridae/epidemiologia , Infecções por Parvoviridae/imunologia , Parvovirus B19 Humano , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA